Xenon Pharmaceuticals Inc. (XENE)
NEUTRALFundamental
29
Kurs
$60.53
Marktkapitalisierung
$5.88B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$8M
Geschäftsjahr zum 31.12.2025
Nettogewinn
$-346M
Geschäftsjahr zum 31.12.2025
Freier Cashflow
$-280M
Gesamtes Eigenkapital
$582M
Gesamtverbindlichkeiten
$51M
Current Ratio
21.02
Zinsdeckungsgrad
-
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$81.30
Aktueller Kurs
$60.53
Sicherheitsmarge
+25.5%
Innerer-Wert-Spanne
$77.23 - $85.36
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-59.5%
P/B-Verhältnis
4.72
P/FCF
-
Bruttomarge
-
ROIC
-27.9%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
-27.9%
WACC
8.0%
ROIC − WACC
-35.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (6)
- Price CAGR 22.95%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 96% Buy
- Share Dilution 1.9%
Nicht bestanden (11)
- EPS shows upward trend
- ROIC -27.9%
- P/B Ratio 4.72
- Operating Margin -Infinity%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -44.0%
- Revenue Growth 5Y -25.3%
- Earnings Surprise avg 0.5%
- Piotroski F-Score 2/9
Nicht verfügbar (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienanzahl ist stabil
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. | President, CEO & Director | 49 |
| Mr. Thomas Patrick Kelly J.D. | Chief Financial Officer | 54 |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corporate Secretary | 57 |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer | 54 |
| Mr. Darren S. Cline M.B.A. | Chief Commercial Officer | 61 |
| Dr. Matthew D. Ronsheim Ph.D. | Chief Operating Officer | 53 |
| Ms. Shelley McCloskey B.A. | Executive Vice President of Human Resources | 65 |
| Dr. Robin P. Sherrington Ph.D. | Executive Vice President of Strategy & Innovation | 64 |
| Dr. James R. Empfield Ph.D. | Executive Vice President of Drug Discovery | 64 |
| Ms. Colleen Alabiso | Senior Vice President of Corporate Affairs | - |
Prüfungsrisiko
5
Vorstandsrisiko
1
Vergütungsrisiko
8
Aktionärsrechterisiko
3
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for XENE, sourced from Markets Gazette.
- 3/9/2026POSITIVEXenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Xenon Pharmaceuticals Inc. experienced a significant share price surge following the release of positive Phase 3 clinical trial data for its drug azetukalner. The pivotal study demonstrated a substantial reduction in monthly seizures for patients treated with the drug. This success paves the way for Xenon to file for FDA approval in 2026. The strong clinical results and clear regulatory path are highly encouraging for investors, potentially positioning azetukalner as a significant new treatment option and driving future revenue growth for the company.
via Markets Gazette